OBJECTIVE: To evaluate variation in outpatient antibiotic utilization among US commercial health plans and the implications of this variation for cost and quality. STUDY DESIGN AND METHODS: We measured antibiotic utilization rates among 229 US commercial health plans that participated in the 2005 Healthcare Effectiveness Data and Information Set. Rates were adjusted to account for health plan age and sex distribution. To estimate antibiotic costs, we multiplied utilization data for each drug class by national estimates of intraclass distribution of drugs, duration of therapy, and median average wholesale price. RESULTS: Antibiotic utilization rates varied markedly among plans, ranging from 0.64 antibiotic fills per member per year (PMPY) at the 5th percentile of plans to 1.08 fills PMPY at the 95th percentile, with a mean of 0.88 (SD +/- 0.15) antibiotic fills PMPY. US census region was the strongest predictor of antibiotic utilization. Antibiotic costs averaged $49 PMPY and ranged from $34 to $63 PMPY among plans at the 5th and 95th percentiles of cost, respectively. If a health plan with 250,000 members at the 90th percentile of antibiotic costs reduced its costs to the 25th percentile, annual drug cost savings would be approximately $4.1 million. CONCLUSIONS: Antibiotic utilization varies substantially among commercial health plans and is not accounted for by differences in the age and sex distribution of plan members. Because reducing rates of antibiotic utilization is likely to lower costs and improve quality, high-utilizing plans may reap considerable rewards from investing in programs to reduce the overuse of antibiotics.
OBJECTIVE: To evaluate variation in outpatient antibiotic utilization among US commercial health plans and the implications of this variation for cost and quality. STUDY DESIGN AND METHODS: We measured antibiotic utilization rates among 229 US commercial health plans that participated in the 2005 Healthcare Effectiveness Data and Information Set. Rates were adjusted to account for health plan age and sex distribution. To estimate antibiotic costs, we multiplied utilization data for each drug class by national estimates of intraclass distribution of drugs, duration of therapy, and median average wholesale price. RESULTS: Antibiotic utilization rates varied markedly among plans, ranging from 0.64 antibiotic fills per member per year (PMPY) at the 5th percentile of plans to 1.08 fills PMPY at the 95th percentile, with a mean of 0.88 (SD +/- 0.15) antibiotic fills PMPY. US census region was the strongest predictor of antibiotic utilization. Antibiotic costs averaged $49 PMPY and ranged from $34 to $63 PMPY among plans at the 5th and 95th percentiles of cost, respectively. If a health plan with 250,000 members at the 90th percentile of antibiotic costs reduced its costs to the 25th percentile, annual drug cost savings would be approximately $4.1 million. CONCLUSIONS: Antibiotic utilization varies substantially among commercial health plans and is not accounted for by differences in the age and sex distribution of plan members. Because reducing rates of antibiotic utilization is likely to lower costs and improve quality, high-utilizing plans may reap considerable rewards from investing in programs to reduce the overuse of antibiotics.
Authors: H Seppälä; T Klaukka; J Vuopio-Varkila; A Muotiala; H Helenius; K Lager; P Huovinen Journal: N Engl J Med Date: 1997-08-14 Impact factor: 91.245
Authors: Guillermo L Monroy; Paritosh Pande; Ryan M Nolan; Ryan L Shelton; Ryan G Porter; Michael A Novak; Darold R Spillman; Eric J Chaney; Daniel T McCormick; Stephen A Boppart Journal: J Biomed Opt Date: 2017-12 Impact factor: 3.170
Authors: Mallika L Mundkur; Jessica Franklin; Krista F Huybrechts; Michael A Fischer; Aaron S Kesselheim; Jeffrey A Linder; Joan Landon; Elisabetta Patorno Journal: Drug Saf Date: 2018-12 Impact factor: 5.606
Authors: Johannes Hjm Uijen; Patrick Je Bindels; François G Schellevis; Johannes C van der Wouden Journal: Scand J Prim Health Care Date: 2011-06 Impact factor: 2.581
Authors: Rachael Boggon; Richard Hubbard; Liam Smeeth; Martin Gulliford; Jackie Cassell; Susan Eaton; Munir Pirmohamed; Tjeerd-Pieter van Staa Journal: BMC Pulm Med Date: 2013-05-31 Impact factor: 3.317